NewsBenzingaClover Health Investments eleva su guía de ventas para el ejercicio fiscal 2026 de $2.920B-$3.000B a $2.970B-$3.000B frente a los $2.954B estimados Clover Health Investments eleva su guía de ventas para el ejercicio fiscal 2026 de $2.920B-$3.000B a $2.970B-$3.000B frente a los $2.954B estimados Benzinga 2026.11.04 21:17 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform Quanterix Affirms FY2026 Sales Guidance of $142.000M-$146.000M vs $143.357M Est
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform